Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 2Mesothelioma 2Lung Neoplasms 2Esophageal Neoplasms 2Thymus Neoplasms 1Sarcoma, Ewing 1Neoplasms, Germ Cell and Embryonal 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Trastuzumab 77Capecitabine 59Cyclophosphamide 54Paclitaxel 51Docetaxel 49Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 25exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Everolimus 17Taxes 16Epirubicin 15Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13pertuzumab 12palbociclib 12liposomal doxorubicin 11Magnetic Resonance Spectroscopy 11Filgrastim 11Cisplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × Plicamycin × Clear all
NCT01624090 2019-12-30

Mithramycin for Lung, Esophagus, and Other Chest Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
16 enrolled 13 charts
BreastGastrointestinalOther solid neoplasmThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡